Navigation Links
Stem cell therapy studies for stroke, cerebral palsy prepare for clinical trials
Date:1/29/2008

Finding answers about optimal dosage and timing for stem cell therapy in adults with strokes and newborns with ischemic injuries is a goal of two new federally funded studies.

The answers are critical before clinical trials can begin, says Dr. Cesario V. Borlongan, neuroscientist at the Medical College of Georgia and Charlie Norwood Veterans Affairs Medical Center. He is principal investigator on the National Institutes of Health grants totaling $6 million that also will explore long-term benefits of cell therapy.

If these additional laboratory studies replicate the promising results of the pilot studies, which indicate about a 25 percent improvement in recovery over controls, MCG and VA researchers hope to begin clinical trials in new ischemic injuries in adults and children within two years.

We are looking at different procedures that we can adopt from the laboratory for the clinic, Dr. Borlongan says. We have at least 10 years of basic research that clearly shows that stem cells have the potential to be a new therapy for adult stroke.

This is a whole new paradigm, a totally different way of targeting disease, says Dr. David Hess, chair of the MCG Department of Neurology and co-investigator. Clot buster tPA is the only drug that is FDA-approved to treat ischemic strokes; an often-delayed diagnosis and a three-hour treatment window mean only a small percentage of patients get it.

Drs. Hess and Borlongan say cell therapy could eventually be used alone or in conjunction with tPA, if recovery is not sufficient. Pilot studies indicate cell therapy can be of benefit up to seven days after a stroke but that two days out is the optimal time of delivery. This will allow us to enroll patients who get tPA, give us plenty of time to assess them and prepare the cells, says Dr. Borlongan.

Their success in an adult stroke model led the researchers to explore the potential for helping babies recover from hypoxic ischemia, a loss of blood and oxygen that can result in cerebral palsy, broadly defined as a brain injury that occurs before or during birth.

Ischemic brain injury accounts for about 10 percent of cerebral palsy and about 80 percent of strokes.

They found young, developing brains more adaptable to injury and better able to recover even without intervention. Very young patients may be the biggest beneficiaries of cell therapy, says Dr. James E. Carroll, chief of the MCG Section of Pediatric Neurology and a co-investigator. Our hope is that cell therapy will speed recoveries of babies who have experienced a brain injury at birth, he says. You want to increase the spontaneous recovery, enhance the neurogenesis that is already occurring in the brains of these young patients, adds Dr. Borlongan. They have models for mild, moderate and severe ischemic injury to reflect damage that can result from scenarios such as an umbilical cord wrapped around the fetus neck or placental abruption, which disrupts the fetus source of oxygen and nutrients. Researchers expect that cell therapy likely would be used as an adjunct to hypothermia, a new FDA-approved treatment for hypoxic ischemic injury in babies that appears to improve outcomes by reducing metabolic rates, including oxygen requirements, in the hours following an injury.

Given intravenously, the adult, bone marrow-derived stem cell line, developed by Cleveland-based biopharmaceutical company Athersys, Inc., seems to hone in on the area of injury where it works multiple ways. While only a small fraction of the cells actually survive and mature into neurons more survive in the baby model than the adult trophic factors they secrete significantly enhance recovery of brain cells injured by lack of oxygen and help grow new blood vessels.

Nothing seems to help the core of the ischemic area in stroke, which is formed within hours of injury; even when cells are placed directly into the core, they do not survive in the area, which is devoid of a blood supply, Dr. Borlongan says. However the cells and their trophic factors can dramatically reduce the penumbra, the area of damaged cells surrounding the core, an area that can continue to grow several days after injury. Interestingly, these undifferentiated stem cells dont seem to interest the immune system, so immunosuppression is not required as it typically is for organ transplants, even when a human cell is placed in a rat, Dr. Borlongan says. Also, pilot studies that have followed rat models for two months after transplant a long time considering the average rat lives two years havent found any signs of tumor formation, which is a concern with stem cells. The new studies will follow transplants for six months, to ensure that efficacy and safety hold up, Dr. Borlongan says.

Theyll explore dose ranges between 400,000 and 40 million cells. We want to see, if we implant more cells, will it be more beneficial" says Dr. Borlongan. It may not be the more the merrier.

In preparation for clinical trials, the researchers already have clinical advisory groups for the studies and have begun submitting grant proposals and talking with the FDA. Smaller studies in non-human primate models may also be required before clinical trials begin, Dr. Borlongan says.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

Related medicine news :

1. New therapy effectively treats deep vein thrombosis
2. New Gene-Based Therapy an Alternative to Vytorin and Statins in Heart Disease Prevention and Treatment
3. MaxCyte to Present at the Phacilitate Cell and Gene Therapy Forum 2008
4. Siemens Receives FDA 510(K) Clearance for Next Generation Radiation Therapy Solution
5. Advanced Therapy Aids Stroke Patients
6. The RNA drug revolution -- a new approach to gene therapy
7. Combination therapy improves survival for certain prostate cancer patients
8. Debate over safety of gene therapy trials focuses on issue of informed consent
9. Hormone Therapy Only Helps Some Older Men With Prostate Cancer
10. Cell division studies hint at future cancer therapy
11. Combo Therapy Shows Promise in Treating Brain Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stem cell therapy studies for stroke, cerebral palsy prepare for clinical trials
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: